[go: up one dir, main page]

MX2016006584A - Métodos y composiciones para tratar los depósitos de amiloide. - Google Patents

Métodos y composiciones para tratar los depósitos de amiloide.

Info

Publication number
MX2016006584A
MX2016006584A MX2016006584A MX2016006584A MX2016006584A MX 2016006584 A MX2016006584 A MX 2016006584A MX 2016006584 A MX2016006584 A MX 2016006584A MX 2016006584 A MX2016006584 A MX 2016006584A MX 2016006584 A MX2016006584 A MX 2016006584A
Authority
MX
Mexico
Prior art keywords
compositions
methods
mammal
amyloid deposits
blood sample
Prior art date
Application number
MX2016006584A
Other languages
English (en)
Inventor
L Davidson Beverly
T Hyman Bradley
HUDRY Eloise
Original Assignee
Univ Iowa Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Iowa Res Found filed Critical Univ Iowa Res Found
Publication of MX2016006584A publication Critical patent/MX2016006584A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)

Abstract

La presente divulgación proporciona los métodos para determinar A-beta en un mamífero antes y después del tratamiento de un amiloidosis, que comprende obtener una primera muestra de sangre del mamífero; administrar al mamífero un tratamiento para una amiloidosis; obtener una segunda muestra de sangre del mamífero; cuantificar un nivel de a-beta en la primera muestra de sangre y en la segunda muestra de sangre; y determinar el nivel de A-beta en el mamífero antes y después del tratamiento de la amiloidosis.
MX2016006584A 2013-11-20 2014-11-20 Métodos y composiciones para tratar los depósitos de amiloide. MX2016006584A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361906811P 2013-11-20 2013-11-20
PCT/US2014/066658 WO2015077473A1 (en) 2013-11-20 2014-11-20 Methods and compositions for treating amyloid deposits

Publications (1)

Publication Number Publication Date
MX2016006584A true MX2016006584A (es) 2016-09-06

Family

ID=53180142

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016006584A MX2016006584A (es) 2013-11-20 2014-11-20 Métodos y composiciones para tratar los depósitos de amiloide.

Country Status (10)

Country Link
US (1) US20170336395A1 (es)
EP (1) EP3071240B1 (es)
JP (1) JP6592435B2 (es)
KR (1) KR20160079891A (es)
AU (1) AU2014352944A1 (es)
CA (1) CA2931220A1 (es)
ES (1) ES2874704T3 (es)
IL (1) IL245703B (es)
MX (1) MX2016006584A (es)
WO (1) WO2015077473A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017318717B2 (en) * 2016-09-02 2024-10-24 Spark Therapeutics, Inc. Methods and vectors for treating CNS disorders
EP3534892A4 (en) * 2016-11-04 2020-05-27 The Children's Hospital of Philadelphia GENE TRANSFER COMPOSITIONS, METHODS AND USE FOR TREATING NEURODEGENERATIVE DISEASES
CN113557243A (zh) * 2018-11-28 2021-10-26 普利维尔治疗公司 用于神经变性疾病的基因疗法
US12514901B2 (en) * 2019-08-07 2026-01-06 Texas Tech University System AD36E4ORF1: a therapeutic treatment for Alzheimer's disease
KR20220082050A (ko) * 2019-10-16 2022-06-16 코넬 유니버시티 알츠하이머병에 대한 유전자 요법

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3002156A (en) * 1961-09-26 pumped solid state maser
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US6855314B1 (en) 2000-03-22 2005-02-15 The United States Of America As Represented By The Department Of Health And Human Services AAV5 vector for transducing brain cells and lung cells
US6468524B1 (en) 2000-03-22 2002-10-22 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services AAV4 vector and uses thereof
JP4511830B2 (ja) * 2001-08-17 2010-07-28 ワシントン・ユニバーシティ アルツハイマー病のアッセイ方法
WO2004108922A2 (en) * 2003-04-25 2004-12-16 The Trustees Of The University Of Pennsylvania Use of aav comprising a capsid protein from aav7 or aav8 for the delivery of genes encoding apoprotein a or e genes to the liver
WO2007022015A1 (en) * 2005-08-12 2007-02-22 Georgetown University Methods to evaluate amyloid beta-lowering agents using wild-type mice
EP1865326B1 (en) * 2006-06-08 2011-09-07 FU Berlin Assay for the diagnosis of Alzheimer's Disease based on the determination of the ratio of secretase Aß cleavage products
US20080234377A1 (en) * 2007-03-23 2008-09-25 Martek Biosciences Corporation Polyunsaturated fatty acids for treatment of dementia and pre-dementia-related conditions
KR20130116792A (ko) * 2010-05-24 2013-10-24 더 워싱턴 유니버시티 혈액내 아밀로이드 베타 대사회전을 측정하는 방법
EP2691529B1 (en) * 2011-03-31 2019-06-12 University of Iowa Research Foundation AAV2 particle comprising an AAV2 capsid protein and a vector comprising a nucleic acid encoding a tripeptidyl peptidase 1 (TPP1) for use in treating late infantile ceroid lipofuscinosis (LINCL) in a non-rodent mammal by intraventricular injection or ICV delivery.
EP2511296A1 (en) * 2011-04-12 2012-10-17 Araclón Biotech, S. L. Antibody, kit and method for determination of amyloid peptides
ES2666840T3 (es) * 2011-07-13 2018-05-08 Acumen Pharmaceuticals, Inc. Anticuerpos, kit y método in vitro para detectar beta-oligómeros amiloides

Also Published As

Publication number Publication date
BR112016011258A2 (pt) 2017-09-26
JP2016540977A (ja) 2016-12-28
IL245703B (en) 2022-07-01
ES2874704T3 (es) 2021-11-05
JP6592435B2 (ja) 2019-10-16
EP3071240B1 (en) 2021-01-06
EP3071240A1 (en) 2016-09-28
AU2014352944A1 (en) 2016-06-16
US20170336395A1 (en) 2017-11-23
CA2931220A1 (en) 2015-05-28
KR20160079891A (ko) 2016-07-06
EP3071240A4 (en) 2017-10-11
IL245703A0 (en) 2016-07-31
WO2015077473A1 (en) 2015-05-28

Similar Documents

Publication Publication Date Title
ZA202208792B (en) Methods of treating and preventing graft versus host disease
EA201790398A1 (ru) Способы лечения заболевания печени
MX2021002728A (es) Combinacion de anticuerpos anti-gen 3 de la activacion del linfoncito (lag-3) y anticuerpos anti-muerte celular programada 1 (pd-1) para usarse en el tratamiento de tumores.
MX2016002645A (es) Tratamiento combinado para tratar el glioblastoma.
MX373957B (es) Un método in vitro para detectar un biomarcador de cáncer en un sujeto.
EA201592269A1 (ru) Способы и композиции для снижения иммуносупрессии опухолевыми клетками
EP4321866A3 (en) Gdf-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers
MX2016002423A (es) Composiciones y metodos de diagnostico para el tratamiento de glioblastoma.
EA201592203A1 (ru) Способы лечения таупатии
WO2014205266A3 (en) Compositions and methods for detecting and treating glioblastoma
NZ716643A (en) Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event
MX2018008882A (es) Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro.
EA201591543A1 (ru) Комбинированные терапии для лечения рака с применением микрорнк и ингибиторов egfr-tki
PH12016501051A1 (en) Methods of treasting and preventing alloantibody driven chronic graft versus host disease
MX2023002021A (es) Anticuerpos de union al componente de complemento 1 c1s para usarse en el tratamiento de trastornos autoinmune y aloinmune.
MX377593B (es) Composiciones para usar en el tratamiento de cáncer renal.
BR112015027477A8 (pt) bolus, seus usos, e kit
PH12018501443A1 (en) Methods of administering hepcidin
WO2015013508A3 (en) Methods for diagnosing and treating immune disease
EA201792096A3 (ru) РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА
MX2016006584A (es) Métodos y composiciones para tratar los depósitos de amiloide.
MX2018000528A (es) Dispositivo para la deteccion de proteinas mal plegadas y metodos de uso del mismo.
TR201900665T4 (tr) Diyabetik nefropatinin tedavi yöntemi.
WO2014169011A3 (en) Methods for treating immune diseases
MX2018001493A (es) Gdf-15 como biomarcador de toxicidad hematologica.